In silico: Analysis of retinoblastoma gene and novel drug designi | 31250
Journal of Proteomics & Bioinformatics

Journal of Proteomics & Bioinformatics
Open Access

ISSN: 0974-276X

In silico: Analysis of retinoblastoma gene & novel drug designing

6th International Conference & Expo on Proteomics

March 29-31, 2016 Atlanta, USA

Farhina Pasha

University of Tabuk, KSA

Posters & Accepted Abstracts: J Proteomics Bioinform

Abstract :

The gene for the present study is RB1 which is a Tumor suppressor gene. It regulates cell cycle as a check point for p53 and for other genes as well, specifying cell fate. During the study, Data was mined from NCBI, PubMed, BIND, KEGG, Ensembl, UniProt, SWISS-PROT, InterPro, Pfam, PDB and the tools which were used to gather information are BLAST, CLUSTALW, FSPLICE, FPROM, POLYAH, ORF FINDER and CDART. Data mining was done first at Ground Level Mining in which relevant data sets are collected and then reduced to the minimum size possible through statistical representation. Chromosome Report was studied to determine the chromosome location of the gene under study. The mRNA Report gives detailed information regarding the gene for its identification and transcript sequences. The Peptide Report reveals highly descriptive data regarding protein, SNP regions, position and alleles. A special emphasis was given to protein interactions and blastp result for study of homologous protein sequences. Phylogenetic tree is generated using homologous protein sequences for Phylogenetic Inference and homology with other taxa. The preclinical data of cyclosporine has suggested that it has a significant role in treating retinoblastoma malignancies but the binding of Actinomycin-D with Rb is far better as evident by the low e-total value signifying its greater affinity. Therefore the drug is suggested as a potential drug for future in treatment of retinoblastoma and associated retinoblastoma malignancies.

Biography :